Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Kobi Tzdaka"'
Autor:
Alexandra Aronin, Shira Amsili, Tatyana B Prigozhina, Kobi Tzdaka, Jacob Rachmilewitz, Noam Shani, Mark L Tykocinski, Michal Dranitzki Elhalel
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77050 (2013)
BACKGROUND:New strategies for the treatment of hepatocellular carcinoma (HCC) are needed, given that currently available chemotherapeutics are inefficient. Since tumor growth reflects the net balance between pro-proliferative and death signaling, age
Externí odkaz:
https://doaj.org/article/2abdbdcf2b784c789083154a29afa674
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Cytotoxic T-lymphocyte antigen 4 (CTLA4)-FasL, a homo-hexameric signal converter protein, is capable of inducing robust apoptosis in malignant cells of the B-cell lineage expressing its cognate B7 and Fas targets, while sparing nonmalignant ones. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8acdcf063baf664e37a78b4888b1cb1
https://doi.org/10.1158/1535-7163.c.6542272.v1
https://doi.org/10.1158/1535-7163.c.6542272.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
(a) Receptors expression on human cell lines and mouse BCL-1 splenocytes. (b) Anti CTLA4-FasL antibodies are formed in treated mice. (c) Neutralizing anti CTLA4-FasL antibodies are formed in treated mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b964846c2e67de8d26eac159f86a21bb
https://doi.org/10.1158/1535-7163.22519081.v1
https://doi.org/10.1158/1535-7163.22519081.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Table S1. Summary of the Toxicokinetic Parameters of CTLA4-FasL in mouse Plasma at the first injection (Day 1) and the third injection (Day 5) Table S2. Summary of the Pharmacokinetic parameters in a single dose of CTLA4-FasL in Cynomolgus monkey pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c90efa3cfd76a11505c99d79171c4e
https://doi.org/10.1158/1535-7163.22519057.v1
https://doi.org/10.1158/1535-7163.22519057.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1700b3bdd4de82a3cc3d1d6b0fa0dc1e
https://doi.org/10.1158/1535-7163.22519060.v1
https://doi.org/10.1158/1535-7163.22519060.v1
Autor:
Alexandra Aronin, Shira Amsili, Yosi Gozlan, Liat Ben Gigi Tamir, Jitka Yehudith Sagiv, Fanny Shkedy, Tatyana B. Prigozhina, Michal Dranitzki Elhalel, Noam Shani, Efi Makdasi, Kobi Tzdaka, Mark L. Tykocinski
Publikováno v:
Molecular cancer therapeutics. 19(2)
Cytotoxic T-lymphocyte antigen 4 (CTLA4)-FasL, a homo-hexameric signal converter protein, is capable of inducing robust apoptosis in malignant cells of the B-cell lineage expressing its cognate B7 and Fas targets, while sparing nonmalignant ones. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c73512ea9bb6c257bbc6a012b050027
https://pubmed.ncbi.nlm.nih.gov/31871267
https://pubmed.ncbi.nlm.nih.gov/31871267
Autor:
Efi Makdasi, Michal Dranitzki Elhalel, Kobi Tzdaka, Fanny Szafer, Alexandra Aronin, Noam Shani, Tatyana B. Prigozhina, Shira Amsili
Publikováno v:
Cancer letters. 400
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) demonstrates specific anti-cancer activity, but insufficient efficacy in patients. A fusion protein Fn14·TRAIL, that combines soluble TRAIL molecule with a specific TWEAK receptor Fn14,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b2d5ebbe15c1f259c7c4e5fbd0aea0
https://pubmed.ncbi.nlm.nih.gov/28455246
https://pubmed.ncbi.nlm.nih.gov/28455246
Autor:
Shira Amsili, Per Edebrink, Tatyana B. Prigozhina, Leonid Grinmann, Michal Dranitzki Elhalel, Mari-Anne Rauvola, Roy Shen, Alexandra Aronin, Noam Shani, Fanny Szafer, Kobi Tzdaka
Publikováno v:
Journal of Hematology & Oncology
Non-Hodgkin lymphomas (NHLs) account for 4% of all malignancies. 5-year survival rate increased to 50% with new treatment modalities, however there is need for new effective treatment for the more aggressive, relapsing forms. Recently, CTLA4-FasL, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1c406d19696fbcac4080a607994613
https://doi.org/10.1186/s13045-014-0064-6
https://doi.org/10.1186/s13045-014-0064-6
Autor:
Michal Dranitzki Elhalel, Alexandra Aronin, Noam Shani, Tatyana B. Prigozhina, Shira Amsili, Kobi Tzdaka, Mark L. Tykocinski, Jacob Rachmilewitz
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77050 (2013)
PLoS ONE
PLoS ONE
Background: New strategies for the treatment of hepatocellular carcinoma (HCC) are needed, given that currently available chemotherapeutics are inefficient. Since tumor growth reflects the net balance between pro-proliferative and death signaling, ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e8bfd3bb4d9e06acc006244ddd87c6
http://europepmc.org/articles/PMC3794952?pdf=render
http://europepmc.org/articles/PMC3794952?pdf=render
Autor:
Michal Dranitzki Elhalel, Noam Shani, Alexandra Aronin, Tatyana B. Prigozhina, Moshe Baru, Efi Makdasi, Shira Amsili, Kobi Tzdaka, Fanny Shkedy
Publikováno v:
Blood. 126:1553-1553
The bi-functional drug CTLA4-FasL (KAHR-102) is a fusion protein composed of the extracellular domains of CTLA4 and FasL. It naturally forms a stable homo-hexamer capable of targeting two different cellular receptors; the CTLA4 domains target B7 rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6697369d32e9a0219dbd966fa994945f
https://doi.org/10.1182/blood.v126.23.1553.1553
https://doi.org/10.1182/blood.v126.23.1553.1553